'False hopes': FDA re­leas­es brief­ing docs on con­tro­ver­sial preterm birth med Mak­e­na ahead of ad­comm

The FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) dropped its brief­ing doc­u­ments spelling out why Co­vis’ con­tro­ver­sial preterm birth drug Mak­e­na should be pulled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER